In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

In animal models, the incretin hormone GLP-1 affects Alzheimer’s disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMR(glc)) in AD. In this 26-week trial, we randomized 38 patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Aging Neurosci
Hlavní autoři: Gejl, Michael, Gjedde, Albert, Egefjord, Lærke, Møller, Arne, Hansen, Søren B., Vang, Kim, Rodell, Anders, Brændgaard, Hans, Gottrup, Hanne, Schacht, Anna, Møller, Niels, Brock, Birgitte, Rungby, Jørgen
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2016
Témata:
Neuroscience
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4877513/
https://ncbi.nlm.nih.gov/pubmed/27252647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnagi.2016.00108
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky